The main research objective of the Ayad laboratory is to identify therapeutic combinations for glioblastoma and medulloblastoma. We are utilizing a multi-omics approach to target epigenetic and kinase pathways simultaneously. We are working closely with chemists to generate novel brain/spinal cord penetrant epigenetic enzyme and kinase inhibitors. We also collaborate with a large group of basic scientists and clinicians to move our small molecules into clinical trials for incurable forms of brain cancer.